CURE | SPXL | CURE / SPXL | |
Gain YTD | -12.107 | 12.460 | -97% |
Net Assets | 159M | 5.55B | 3% |
Total Expense Ratio | 0.93 | 0.87 | 107% |
Turnover | 23.00 | 29.00 | 79% |
Yield | 1.40 | 0.91 | 153% |
Fund Existence | 14 years | 17 years | - |
CURE | SPXL | |
---|---|---|
RSI ODDS (%) | N/A | 1 day ago82% |
Stochastic ODDS (%) | 1 day ago89% | 1 day ago85% |
Momentum ODDS (%) | 1 day ago82% | N/A |
MACD ODDS (%) | 1 day ago89% | 1 day ago90% |
TrendWeek ODDS (%) | 1 day ago90% | 1 day ago90% |
TrendMonth ODDS (%) | 1 day ago90% | 1 day ago90% |
Advances ODDS (%) | 4 days ago90% | 1 day ago90% |
Declines ODDS (%) | 9 days ago90% | 19 days ago89% |
BollingerBands ODDS (%) | 1 day ago90% | 1 day ago85% |
Aroon ODDS (%) | 1 day ago90% | 1 day ago90% |
A.I.dvisor indicates that over the last year, CURE has been closely correlated with IQV. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if CURE jumps, then IQV could also see price increases.
Ticker / NAME | Correlation To CURE | 1D Price Change % | ||
---|---|---|---|---|
CURE | 100% | +1.36% | ||
IQV - CURE | 68% Closely correlated | +2.54% | ||
GEHC - CURE | 65% Loosely correlated | +1.14% | ||
TMO - CURE | 61% Loosely correlated | +0.69% | ||
REGN - CURE | 58% Loosely correlated | -0.27% | ||
IDXX - CURE | 57% Loosely correlated | +2.77% | ||
More |
A.I.dvisor indicates that over the last year, SPXL has been loosely correlated with MSFT. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if SPXL jumps, then MSFT could also see price increases.
Ticker / NAME | Correlation To SPXL | 1D Price Change % | ||
---|---|---|---|---|
SPXL | 100% | +1.11% | ||
MSFT - SPXL | 63% Loosely correlated | +0.55% | ||
AAPL - SPXL | 62% Loosely correlated | +0.06% | ||
AMZN - SPXL | 60% Loosely correlated | -0.34% | ||
META - SPXL | 59% Loosely correlated | -0.30% | ||
NVDA - SPXL | 56% Loosely correlated | -0.14% | ||
More |